research A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).
Topical calcitriol is safe for preventing hair loss during chemotherapy.
Search
for
Sort by
Research
900-930 / 1000+ results
research THU0189 Safety of four treatment regimens in early rheumatoid arthritis
All four treatments for early rheumatoid arthritis had similar safety profiles.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Application of Baricitinib in Dermatology
Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
research Managing Azathioprine-Induced Myelosuppression and Alopecia Totalis: Lessons from a SLE Patient
Monitor for early signs of myelosuppression, like hair loss, in patients on azathioprine to manage side effects.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Candida antigen immunotherapy versus steroid in the treatment of alopecia areata
Candida antigen is an effective and promising treatment for alopecia areata.
research Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
research Efficacy of mesalazine in children with moderate to severe alopecia areata: case series of 18 patients
Mesalazine showed limited effectiveness in treating children with severe alopecia areata.
research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database
Some drugs used to treat inflammation may cause hair loss.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research Balint’s syndrome—missed or mistaken?
The document concludes that early diagnosis of Balint's syndrome is crucial for effective treatment and that understanding drug interactions, like between ritonavir and statins, is important for patient care.
research A combination of low-dose systemic etretinate and topical calcipotriol/betamethasone dipropionate treatment for hyperkeratosis and itching in Olmsted syndrome associated with a TRPV3 mutation
The combined treatment effectively managed severe skin issues in Olmsted syndrome.
research Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata
SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.
research Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
Temozolomide improves survival in grade III glioma patients without harming quality of life.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Advances in the mechanism and new therapies of alopecia areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Treatment of tinea capitis caused by Microsporum ferrugineum with itraconazole.
Itraconazole effectively treats scalp fungus, with continuous use more effective than pulse therapy.
research Baricitinib in the Management of Coexisting Alopecia Areata and Atopic Dermatitis: A Case Report
Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
research Attending persistent T cell activation in alopecia areata : A therapeutic option
Blocking certain proteins on immune cells may help treat alopecia areata.
research Methotrexate for induction of remission in ulcerative colitis
Methotrexate is not proven effective for inducing remission in ulcerative colitis.
research Efficacy of Topical Clobetasol Propionate 0.05% Ointment and Topical Tacrolimus 0.1% Ointment in Treatment of Alopecia Areata.: RCT
Topical clobetasol propionate 0.05% ointment is more effective in promoting hair regrowth in patients with alopecia areata than topical tacrolimus 0.1% ointment.
research PIGMENTATION IN ALOPECIA TOTALIS
Treatment with corticosteroids and zinc injections can help hair regrowth and restore pigmentation in alopecia totalis.
research Efficacy and Safety of Topical Corticosteroid Treatment under Occlusion for Severe Alopecia Areata in Children. A single-center retrospective analysis
Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
research Topical Tacrolimus, Clobetasol, and Minoxidil (TCM) for Primary Cicatricial Alopecias: A Retrospective Analysis of Clinical Outcomes and Safety
TCM is an effective and safe treatment for primary cicatricial alopecias.
research Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
research The Efficacy of Intralesional Pentoxifylline Injection versus the Standard Intralesional Corticosteroid Injection in The Treatment of Alopecia Areata
Combining pentoxifylline with corticosteroids improves alopecia areata treatment.